{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-028179","form_type":"8-K","ticker":"MED","cik":"0000910329","company_name":"MEDIFAST INC","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.969028+00:00","generated_at":"2026-06-22T11:07:24.163246+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Medifast Q3 revenue down 5.6%; cuts FY2022 revenue and EPS guidance on macro headwinds","bullets":["Revenue $390.4M (-5.6% YoY); net income $36.2M ($3.27 diluted EPS). Non-GAAP adjusted EPS $3.32.","Active earning OPTA VIA Coaches 66,200 (+8.5% YoY) but revenue per coach fell 12.9% to $5,897.","Full-year 2022 revenue guidance cut to $1.51B-$1.59B from $1.58B-$1.66B; non-GAAP EPS to $11.61-$13.05 from $12.70-$14.10.","Gross margin 72.5% vs 74.3% prior year; cash $69.7M, zero debt; completed $100M ASR program.","Quarterly dividend of $1.64 per share declared; Euromonitor ranked OPTA VIA #1 U.S. weight loss program by revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-028179","json":"https://secwatch.observer/filing/0001628280-22-028179.json","markdown":"https://secwatch.observer/filing/0001628280-22-028179.md","text":"https://secwatch.observer/filing/0001628280-22-028179.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/910329/000162828022028179/0001628280-22-028179-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/910329/000162828022028179/med-20221103form8xk.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T11:07:24.163246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8e074668ee26ffc654bf576b954c8bb54b08b460","claim":"MEDIFAST INC reported the third quarter ended September 30, 2022 results: revenue $390.4 million, net income $36.2 million, EPS $3.27 per diluted share.","evidence_excerpt":"Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTA VIA® , today reported results for the third quarter ended September 30, 2022. Third Quarter 2022 • Revenue of $390.4 million, with revenue per active earning coach of $5,897 • Independent active earning OPTA VIA Coaches of 66,200 • Net income of $36.2 million (non-GAAP adjusted net income of $36.8 million) • Earnings per diluted share of $3.27 (non-GAAP adjusted EPS of $3.32)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/910329/000162828022028179/0001628280-22-028179-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$390.4 million"},{"label":"Net income","value":"$36.2 million"},{"label":"EPS","value":"$3.27 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c0f2d9d2b97facef95a482d57a0daa9156819a55","claim":"MEDIFAST INC reported full-year 2022 results: revenue $1.51 billion to $1.59 billion, EPS $11.61 to $13.05. Guidance lowered.","evidence_excerpt":"The company now anticipates that full-year 2022 revenue to be in the range of $1.51 billion to $1.59 billion, down from the previously announced range of $1.58 billion to $1.66 billion that was previously disclosed. The company expects full-year 2022 non-GAAP diluted EPS to be in the range of $11.61 to $13.05, down from the previously announced range of $12.70 to $14.10.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/910329/000162828022028179/0001628280-22-028179-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2022"},{"label":"Revenue","value":"$1.51 billion to $1.59 billion"},{"label":"EPS","value":"$11.61 to $13.05"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}